ModifiedColorado Rocky Mountain Health PlansPolicy CS051.Q

Gynecomastia Surgery (Mastectomy) Coverage Criteria

Defines medical necessity criteria and coding for mastectomy to treat gynecomastia for Colorado Rocky Mountain Health Plans members, including adults and minors, and relates to surgical and diagnostic evaluation requirements.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGynecomastia Surgery (Mastectomy) Coverage Criteria

Policy CodePolicy CS051.Q

Change TypeRevised clinical criteria and laboratory testing guidance

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization for CPT 19300 and document that all medical necessity criteria are met, including grade, duration, prior medical therapy, and supporting evaluation.

SourceLink

POLICY UPDATE CHANGES

Revised coverage criteria for a mastectomy to treat Gynecomastia in a male, including modifications to evaluation and laboratory testing language and examples.

Removed content/language pertaining to the state of Louisiana.

Added language that this Medical Policy does not apply to the state of Nebraska; refer to the state-specific policy version.

CPT 19300procedure code listed

Grade II-IVeligible gynecomastia grades

>=2 yrspolicy duration threshold

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3+guideline sources cited

3 entriesrecent revisions

Coverage Criteria for Mastectomy to Treat Gynecomastia

Mastectomy for gynecomastia (medical necessity criteria)

Covered when ALL of the following are met for males (separate age statements present):

Stage and symptoms: Gynecomastia stage II, III, or IV with moderate to severe chest pain causing a Functional or Physical Impairment (the inability to participate in athletic events, sports, or social activities alone is not considered a Functional or Physical Impairment).ASPS/modified grading

Applies to both minors and adults per policy text

Tissue type: Glandular breast tissue is the primary cause of gynecomastia (not pseudogynecomastia) and must be documented on physical exam and/or mammography.document glandular predominance

Pseudogynecomastia (fatty enlargement) is not covered unless glandular tissue is primary cause.

Persistence after cessation of causative agents: Persistent gynecomastia after cessation of prescribed medications, nutritional supplements, and appropriate screening(s) of non-prescription and/or recreational drugs or substances known to cause gynecomastia (examples include but are not limited to testosterone, marijuana, asthma drugs, phenothiazines, anabolic steroids, cimetidine, and calcium channel blockers).persistence after stopping agents

Examples of implicated agents are listed in policy.

Duration: Gynecomastia must be present for at least two years (policy statement); ASPS timelines for adolescents and adults are referenced for specific grades and shorter durations when applicable.>= 2 years (policy) and ASPS-specific shorter durations for certain grades

See ASPS guidance for adolescents/adults for grade-specific durations.

Diagnostic evaluation: Appropriate evaluation of medical causes with supporting laboratory testing normal; supporting laboratory testing may include but is not limited to beta-hCG, thyroid studies, sex-hormone binding globulin, estradiol, FSH, LH, prolactin, testosterone, liver enzymes, serum creatinine, and alpha-fetoprotein.supporting labs obtained and normal when required

Breast imaging (ultrasound and/or mammogram) and biopsy if tumor suspected.

Coverage criteria for surgical treatment of gynecomastia

Covered when ALL of the following are met (per ASPS and ASA/EAA guidance):

General: Surgical treatment is for individuals with persistent gynecomastia that does not regress naturally or through subsequent medical therapy; the magnitude and type of surgery depend on the size of breast enlargement and the amount of adipose tissue.

(ASA/EAA guidance)

Adolescent criteria (ASPS 2016): Unilateral or bilateral grade II or III gynecomastia that continues more than one year after pathological causes are ruled out OR continues after six months of failed medical treatment; OR grade IV gynecomastia that continues more than six months after pathological causes are ruled out OR continues after six months of failed medical treatment.

ASPS adolescent recommendations (2016)

Adult criteria (ASPS 2016): Unilateral or bilateral grade III or IV gynecomastia that continues for more than 3 to 4 months after pathological causes are ruled out OR continues after 3 to 4 months of failed medical therapy; breast biopsy is suggested when malignancy is presumed.

ASPS adult recommendations (2016)

Pseudogynecomastia (fatty breast enlargement) is expressly not a covered indication for mastectomy unless the medical record documents that glandular breast tissue is the primary cause of the enlargement on physical examination and/or breast imaging (e.g., mammography).

Note: the FDA information in this policy is informational only. FDA approval alone is not a basis for coverage. Surgical procedures to treat gynecomastia are procedural interventions and are not regulated by the FDA as devices. Coverage determinations remain subject to applicable federal, state, and contractual requirements and laws.

Procedures for gynecomastia are not medically necessary when: the enlargement is due to fatty tissue (pseudogynecomastia) without documented glandular predominance; there is no documented Functional or Physical Impairment attributable to the gynecomastia; or the condition is not persistent after cessation of implicated prescription medications, supplements, or recreational/nonprescription substances and appropriate evaluation. Additionally, surgery that does not meet the policy’s duration and guideline-based persistence requirements would be considered not medically necessary.

Before surgical intervention is considered, conservative and medical management must be attempted and documented when indicated. For adolescents and adults, the policy references ASPS timelines recommending documented trials of medical therapy where applicable (for example, many adolescent cases require up to 6 months of failed medical therapy in certain grades, and adults often require 3–4 months of failed medical therapy for higher grades). Failure to attempt or document these medical therapy durations may render the request noncovered.

Coding and Duration Thresholds

Covered CPT Codes (listed)CPTCovered

19300

Mastectomy for gynecomastia

Applicable codes referenced in policy historymixed

No codes listed

inv-09: Duration thresholds for considering surgery — adolescents vs adults and grade-specific timing

Adolescents (Grade II or III)Persistent >1 year after pathological causes ruled out OR persistent after 6 months of failed medical therapy (ASPS 2016)

Adolescents (Grade IV)Persistent >6 months after pathological causes ruled out OR persistent after 6 months of failed medical therapy (ASPS 2016)

Adults (Grade III or IV)Persistent >3–4 months after pathological causes ruled out OR persistent after 3–4 months of failed medical therapy (ASPS 2016)

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for mastectomy (CPT 19300) to treat gynecomastia and the request must demonstrate that all policy criteria are met. Submit documentation showing gynecomastia stage, duration, evaluation of reversible causes, and trials of medical therapy as applicable.

Prior authorization required for CPT 19300 (mastectomy for gynecomastia).
Request must demonstrate ALL coverage criteria are met (stage II-IV with functional/physical impairment where specified, glandular predominance, persistent after cessation of offending agents, appropriate evaluation/labs).

Denial Risk

Document Gynecomastia Stage

Document gynecomastia stage using a recognized scale (e.g., modified McKinney and Simon, Hoffman, Kohn). Failure to document stage II–IV (or the equivalent grade per cited scales) may result in denial of the request.

Specify grade/stage and laterality (unilateral or bilateral).

Background and Context

Background: Gynecomastia is a benign proliferation of glandular breast tissue in males that can be physiologic (age-related) or secondary to medications, supplements, systemic disease, or tumors. Causes noted in the policy include prescription and nonprescription agents such as testosterone, marijuana, asthma medications, phenothiazines, anabolic steroids, cimetidine, and calcium channel blockers. Management focuses on identifying and treating underlying causes, appropriate laboratory and imaging evaluation, trial of medical therapy when indicated, and surgical removal (mastectomy) for cases that are persistent, symptomatic, and meet grade/duration criteria.

Definitions and Grading

inv-19: Functional or Physical Impairment definition

DefinitionA deviation from normal tissue or organ function resulting in significantly limited capacity to move, coordinate actions, or perform physical activities, including difficulties with physical/motor tasks, independent movement, or performing basic life functions (Medicare, 2023).

Clinical implicationMust produce a significant limitation in physical activities or basic life functions to meet Functional or Physical Impairment criterion for coverage.

Assessment areasPhysical and motor tasks, independent movement, and performing basic life functions are examples of domains considered when documenting impairment.

inv-20: Gynecomastia definition

DefinitionBreast enlargement in boys or men due to a benign (non-cancerous) increase in breast tissue (Endocrine Society, 2022).

Distinction

Policy Revision History

2026-04-01revisionLatest

Template update and removal of content/language pertaining to the state of Louisiana.

2025-11-01revision

Added language that this Medical Policy does not apply to the state of Nebraska and directed readers to the state-specific policy version.

2025-08-01material_revision

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyGynecomastia Surgery (Mastectomy) Coverage Criteria

Policy CodePolicy CS051.Q

Change TypeRevised clinical criteria and laboratory testing guidance

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization for CPT 19300 and document that all medical necessity criteria are met, including grade, duration, prior medical therapy, and supporting evaluation.

SourceLink

On This Page

If stage is not documented or is less than required (e.g., stage I), authorization may be denied.

Denial Risk

Document Duration

Document the duration of gynecomastia and duration of conservative/medical therapy. Requests lacking clear documentation of how long the condition has persisted or the length of any medical therapy trial risk denial.

Include date of onset or first documentation and dates of follow-up showing persistence.
For adolescents: document ≥1 year or other ASPS-specified durations; for adults: document 3–4 months (or as policy specifies) of persistence/failed therapy where applicable.

Documentation Required

Medical Records May Be Requested

Medical records may be required for utilization review. Provide complete clinical documentation to support medical necessity decisions.

Medical records may include clinical notes, imaging (mammogram, breast ultrasound), laboratory results, medication lists, and documentation of counseling regarding cessation of offending agents.
Submission of records does not guarantee coverage; records are used to verify whether policy criteria are met.

Documentation Required

Conservative Measures and Evaluation of Reversible Causes

Ensure conservative measures and evaluation of reversible causes are documented before surgery is authorized. This includes cessation of offending medications/substances and appropriate laboratory evaluation when indicated.

Document attempts to stop or change medications/supplements/substances known to cause gynecomastia and the outcome.
Include results of relevant lab testing (hormone panel, liver enzymes, serum creatinine, alpha-fetoprotein) when performed.

Prior Authorization

Documented Trial and Failure of Medical Therapy Required

A documented trial and failure of medical therapy for the durations specified by policy or specialty guidance is required prior to surgical authorization when applicable. Lack of documented trial or failure of medical therapy per age-specific thresholds may lead to denial.

For adolescents: document >1 year persistence after pathology ruled out or 6 months failed medical treatment for certain grades as specified by ASPS.
For adults: document 3–4 months persistence/failed medical therapy for grade III–IV as specified by ASPS.
Include dates, medications used, dosing, adherence, and assessment of response.

Documentation Required

Additional Documentation Guidance

Additional documentation guidance: include physical exam findings confirming glandular predominance, imaging reports if performed, detailed medication/substance history, and notes addressing functional/physical impairment and pain.

Physical exam documenting glandular vs fatty tissue; imaging (mammography or ultrasound) if used to confirm glandular tissue.
History of offending agents with dates of cessation and response.
Clinical notes addressing pain, functional/physical impairment, and prior conservative management.

Denial Risk

Denial Risk for Incomplete Documentation

Denial risk: requests may be denied if documentation does not show glandular predominance, persistence after stopping offending agents, required stage/grade, or required durations of persistence or failed conservative/medical therapy.

Lack of documentation for glandular tissue (vs pseudogynecomastia) is high risk for denial.
Failure to document cessation of offending agents or outcome, or missing lab/imaging results when indicated, increases denial risk.
Insufficient documentation of required duration of gynecomastia or failed therapy per policy thresholds.

Requires documentation that glandular tissue is the primary cause to meet coverage (pseudogynecomastia/fatty enlargement alone is not covered).

RelevanceUsed to determine eligibility for surgical treatment when other coverage criteria (grade, persistence, impairment) are met.

inv-21: ASPS Gynecomastia scale (Grade II-IV)

Grade IIModerate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest.

Grade IIIModerate breast enlargement exceeding areola boundaries with edges indistinct from the chest with skin redundancy present.

Grade IVMarked breast enlargement with skin redundancy and feminization of the breast.

inv-22: Persistent gynecomastia — does not regress naturally or after appropriate evaluation/therapy and is sustained for policy-defined duration

DefinitionGynecomastia that does not regress naturally or after appropriate medical therapy/evaluation and is sustained for the durations specified by guideline bodies.

Adolescent thresholdsConsidered persistent if >1 year for grade II/III (after pathology ruled out) or >6 months for grade IV, or after 6 months of failed medical therapy (ASPS 2016).

Adult thresholdsConsidered persistent if >3–4 months for grade III/IV after pathology ruled out or after 3–4 months of failed medical therapy (ASPS 2016).

Revised coverage criteria wording and laboratory testing guidance for mastectomy to treat gynecomastia, including changes to examples of supporting laboratory tests (added alpha‑fetoprotein, adjusted hormone testing wording, and removed/altered some thyroid testing mentions); removed reference to Panniculectomy and Body Contouring Procedures policy link.